1.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
; 45(4): 699-702, 2023 Aug.
Artigo
em Chinês
| MEDLINE
| ID: mdl-37654153
RESUMO
Omalizumab,as a biological agent targeting IgE,is a recombinant humanized monoclonal antibody and the first targeted drug approved for treating moderate-to-severe bronchial asthma.By reviewing one case of aspirin-induced asthma complicated with nasosinusitis and otitis media,we discussed the value of omalizumab in the treatment of asthma and its complications,aiming to provide a reference for clinical practice.